The US market for Hemostats and Sealants grew +6.4% YoY in Q219, a slightly lower growth rate vs Q119, with biologic sealants and thrombin hemostats driving the increase.

As reported in SmartTRAK’s Financial Dashboard, every manufacturer in the US Hemostats and Sealants market, except Ethicon, experienced revenue growth in Q219. Leading the way was Baxter, as it capitalized on Ethicon’s supply problems with Surgiflo. Cryolife and Becton Dickinson (BD) both posted strong gains. Ethicon still continued to dominate the overall US Hemostat and Sealants market, with a 40.7% share, down from 48.6% share in Q119. Most of this share shifted to Baxter as the Company continues to chip away at...

Among the many topics covered in the Q219 US Hemostats and Sealants Market Recap* are:

The US Surgical Matrices Market continued its modest growth in Q219, with growth in breast matrices continuing to outpace hernia matrices.

SmartTRAK reports that the US Surgical Matrices market, comprised of matrices used for Breast Reconstruction and Hernia Repair, experienced single digit growth in Q219 according to SmartTRAK estimates. The fast-growing Breast Reconstruction segment slowed to +4.6% YoY during the quarter, while the US Hernia Repair market ticked up slightly to +2.9% YoY.

Among the many topics covered in the Q219 US Surgical Matrices Market Recap* are:

Nate Greenlee has joined the SmartTRAK team as Product Director. Nate has 20+ years experience as a startup founder and executive. Before joining SmartTRAK, Nate helped launch software, big data and new space companies, spanning the financing gamut from bootstrapped, angel-funded and VC funded companies, including Space Adventures, LTD., which  has currently sold over $500 Million in Private Space Flights to the International Space Station.

Hips drive slight acceleration in TJR Market while Knees held steady

With two earnings seasons of 2019 behind us, US Total Joints Market growth of 1.7% for H119, as modeled by SmartTRAK Financial Dashboard, is trending below SmartTRAK projections of 2.6% growth for FY19. This trend is not surprising considering the heightened seasonality we’ve seen over the last few years in H2 due to high patient deductibles. US Total Joints Market growth strengthened slightly to 1.8% for Q219 compared to 1.6% in Q1 driven by...

Among the many topics covered in the Q219 Total Joints Market Recap* are:

Rachel Dolan is SmartTRAK's new Corporate Enterprise Solutions Manager. Rachel has 5+ years in the sports medicine and medical device industries, most recently serving as Account Manager for Stryker Medical working with all organizational levels of hospital customers.

Meet Rachel Dolan:

1. What is your role with SmartTRAK? I am the Corporate Enterprise Solutions Account Manager. I’m responsible for managing and developing client accounts to initiate and maintain favorable relationship with clients.

Join SmartTRAK for breakfast and an Executive Panel on “Advanced Technologies: Shifts in the Spine Landscape” at McCormick Place in Chicago, IL on Sept 26th. A panel of experts will be on hand to discuss the latest in advanced technologies, interbody devices, materials and design, and the impact these changes pose from an FDA regulatory standpoint.

Date:              Thursday, September 26th, 2019
Time:              7:30am-8:30am
Location:      Hyatt Regency McCormick Place,  Chicago, IL
Room:            Jackson Park C&D

Panelists include:

Q219 saw marginal revenue growth amid single-injection momentum and competitive pricing pressure

The numbers are in and now that we are in the second quarter of 2019, the US Joint Fluid market seems to be getting off its slow-ish start of the year, gaining some momentum with the single-injection segment pushing the aggregate total revenue into positive growth, according to the recently published SmartTRAK Financial Dashboard. This, despite relentless and fierce pricing competition in the multi-injection arena. 

Among the many topics covered in the Q219 US Joint Fluid Market Recap* are:

SmartTRAK was once again cited as a trusted source for market data, this time in the Orthofix Q219 Earnings Call and press release.

Brad Mason, Orthofix's President and Chief Executive Officer, referenced the SmartTRAK Market Recap: OrthoBio Report in the press release and stated “Regarding the second quarter results, net sales were in line with our expectations, led by another quarter of outstanding performance in our Biologics products and notably, as reported by SmartTRAK ^®, Orthofix now has the number one market share position in the U.S. cellular allograft segment.”

Terry Hayslett is SmartTRAK's Senior Analyst, Advanced Wound Care. Terry has 20+ years of diverse healthcare experience, including provider reimbursement, corporate compliance, business development, strategic planning, financial analysis and health economics. Before joining SmartTRAK, Terry was  responsible for the global funding and reimbursement function at Mölnlycke Health Care. 

As a Senior Analyst for Wound Care, Terry will manage and maintain the US & WW External Devices (NPWT, Energy, Oxygen and Debridement) and Compression modules and provide reimbursement and regulatory support across all AWC modules.

Meet Terry Hayslett:

1. What is your role with SmartTRAK? As a Senior Analyst for Wound Care, my role is to manage and maintain the US & WW External Devices (NPWT, Energy, Oxygen and Debridement) and Compression modules. I also provide reimbursement and regulatory support across all AWC modules.

SmartTRAK analysts Susan Paquette and Lennart Stadler on European market trends and emerging products and technologies showcased at EWMA 2019.

In many ways, the European Wound Management Association (EWMA) annual meeting is a microcosm of the latest wound care trends in Europe and provides a glimpse of what’s on the horizon in the worldwide (WW) market for Advanced Wound Care (AWC).